Sign In
Buy AXGN
$40.63
+1.17 (+2.97%)
At Close: Jun 03, 2026
Axogen RECON(SM) Clinical Study Completes Subject Follow-up
07:00am, Wednesday, 01'st Sep 2021
RECON is a pivotal study supporting the Company's Biologics License Application (BLA) for Avance® Nerve Graft RECON is a pivotal study supporting the Company's Biologics License Application (BLA) for
Axogen: Renewed Covid-19 Worries Hitting, But The Growth Story Is Very Appealing
06:28am, Wednesday, 25'th Aug 2021
Axogen continues posting double-digit growth in volumes against 2019 levels despite trauma, breast recon, and oral-maxillofacial procedures still well below pre-pandemic levels.
AxoGen's (AXGN) CEO Karen Zaderej on Q2 2021 Results - Earnings Call Transcript
01:22am, Thursday, 05'th Aug 2021
AxoGen's (AXGN) CEO Karen Zaderej on Q2 2021 Results - Earnings Call Transcript
AxoGen (AXGN) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
04:45pm, Wednesday, 28'th Jul 2021
AxoGen (AXGN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Axogen, Inc. Appoints John H. Johnson to Board of Directors
04:01pm, Monday, 19'th Jul 2021
Global leader brings 30+ years of biopharma experience to Axogen, Inc. Board of Directors Global leader brings 30+ years of biopharma experience to Axogen, Inc. Board of Directors
Axogen, Inc. to Report Second Quarter Financial Results and Host Conference Call on August 4, 2021
07:00am, Wednesday, 14'th Jul 2021
ALACHUA, Fla. and TAMPA, Fla., July 14, 2021 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for damage or transection to per
Axogen, Inc. to present at the Jefferies Virtual Healthcare Conference and the JMP Securities Life Sciences Conference
07:00am, Tuesday, 18'th May 2021
ALACHUA, Fla. and TAMPA, Fla., May 18, 2021 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for damage or discontinuity to pe
AxoGen, Inc. (AXGN) CEO Karen Zaderej on Q1 2021 Results - Earnings Call Transcript
01:52pm, Sunday, 09'th May 2021
AxoGen, Inc. (AXGN) CEO Karen Zaderej on Q1 2021 Results - Earnings Call Transcript
AxoGen (AXGN) Reports Q1 Loss, Tops Revenue Estimates
06:25pm, Wednesday, 05'th May 2021
AxoGen (AXGN) delivered earnings and revenue surprises of 52.94% and 8.33%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
Recap: Axogen Q1 Earnings
04:49pm, Wednesday, 05'th May 2021
Shares of Axogen (NASDAQ:AXGN) moved higher in after-market trading after the company reported Q1 results. Quarterly Results Earnings per share increased 57.89% over the past year to ($0.08), which be
Recovering Trauma Cases Should Highlight AxoGen's Improving Execution
12:19pm, Thursday, 11'th Mar 2021
AxoGen has reported two consecutive quarters of double-digit growth despite lower trauma presentations during the pandemic and restrictions on marketing/training efforts. Clinical data continue to sup
Axogen, Inc. Promotes Peter J. Mariani to Executive Vice President and Chief Financial Officer
04:01pm, Monday, 01'st Mar 2021
ALACHUA, Fla., March 01, 2021 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today announced
AxoGen, Inc. (AXGN) CEO Karen Zaderej on Q4 2020 Results - Earnings Call Transcript
11:27pm, Monday, 22'nd Feb 2021
AxoGen, Inc. (AXGN) CEO Karen Zaderej on Q4 2020 Results - Earnings Call Transcript
Axogen, Inc. Reports 2020 Fourth Quarter and Full-Year Financial Results
04:01pm, Monday, 22'nd Feb 2021
ALACHUA, Fla., Feb. 22, 2021 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today reported fi
Axogen, Inc. to Participate at Upcoming February Investor Conferences
07:00am, Thursday, 04'th Feb 2021
ALACHUA, Fla., Feb. 04, 2021 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for damage or discontinuity to peripheral nerves
